Amgen AMGN
NASDAQ AMGN
$468.11 +2.88 (+0.62%)
At close: Nov 11, 2026 · 4:00 PM EST

Amgen (AMGN) Current Deferred Revenue (2009 - 2010)

Updated

Analysis

Amgen (AMGN) Current Deferred Revenue (2009 - 2010) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Vertex Pharmaceuticals 138.90 Bn 106.64 Bn 2.91 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2010 117.00 Mn
Dec 31, 2009 128.00 Mn
API Access

Amgen Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=AMGN&period=max&api_key=YOUR_API_KEY